News from eisai inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 09, 2022, 19:31 ET EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts,...

Apr 26, 2022, 19:31 ET LONG-TERM HEALTH OUTCOMES USING SIMULATION MODEL OF INVESTIGATIONAL LECANEMAB IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE PUBLISHED IN A PEER-REVIEWED JOURNAL, NEUROLOGY AND THERAPY

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced an article about long-term health outcomes of its investigational...

Apr 04, 2022, 10:01 ET Geisinger, Eisai team up to study use of artificial intelligence for early detection and identification of cognitive impairment that could indicate dementias, including Alzheimer's disease

Geisinger and Eisai Inc. today announced a collaborative effort to study the potential effectiveness of an artificial intelligence (AI) tool in the...

Mar 31, 2022, 08:00 ET EISAI TO PRESENT DATA ON NEUROLOGY PORTFOLIO IN THE AREAS OF ALZHEIMER'S DISEASE, SLEEP AND EPILEPSY AT THE 74th AMERICAN ACADEMY OF NEUROLOGY® (AAN) ANNUAL MEETING

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the company will present research from its robust neurology...

Mar 30, 2022, 07:57 ET MEAGAN GOOD SHARES HER SCARE WITH UTERINE CANCER TO ENCOURAGE PEOPLE TO SPOT THE EARLY SIGNS OF ENDOMETRIAL CANCER AS PART OF EISAI AND ADVOCACY PARTNERS' SPOT HER® CAMPAIGN

Actor, director and activist Meagan Good has partnered with FORCE, SHARE, Black Health Matters and Eisai Inc. on the Spot Her® campaign to help raise ...

Mar 22, 2022, 09:02 ET Sysmex Presents Academic Report in Effort to Create a Simple Blood Test to Diagnose Alzheimer's Disease

Sysmex Corporation (Chairman and CEO: Hisashi Ietsugu; hereafter, "Sysmex") and Eisai Co., Ltd. (CEO: Haruo Naito; hereafter, "Eisai") are aiming to...

Mar 21, 2022, 19:30 ET LATEST FINDINGS ON LECANEMAB - CLINICAL EFFICACY, ARIA RATES, BIOMARKERS RELATIONSHIP TO CLINICAL OUTCOMES AND DOSING REGIMENS - PRESENTED AT AD/PD™ 2022 ANNUAL MEETING

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts,...

Mar 10, 2022, 18:30 ET Eisai To Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State Symposium, and Other Pipeline Assets at the AD/PD™ 2022 Annual Meeting

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present research from its robust Alzheimer's...

Mar 03, 2022, 18:30 ET EISAI INITIATES SUBMISSION OF APPLICATION DATA UNDER THE PRIOR ASSESSMENT CONSULTATION SYSTEM IN JAPAN WITH THE AIM OF OBTAINING EARLY APPROVAL FOR INVESTIGATIONAL ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts,...

Jan 24, 2022, 08:05 ET EISAI INC. ANNOUNCES THE APPOINTMENT OF TRICIA BROOKS AS VICE PRESIDENT & HEAD OF OFFICE, GOVERNMENT AFFAIRS AND POLICY

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the expansion of its leadership team to include Tricia Brooks as...

Jan 18, 2022, 18:30 ET FIRST SUBJECT ENROLLED IN PHASE II/III STUDY OF EISAI'S ANTI-MTBR TAU ANTIBODY E2814 FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE (DIAD), CONDUCTED BY DIAN-TU

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the Dominantly Inherited Alzheimer Network Trials Unit...

Jan 14, 2022, 08:08 ET Eisai to Present Research at the 2022 ASCO Gastrointestinal Cancers Symposium in Multiple Tumor Types from its Robust Oncology Portfolio

Eisai announced today the presentation of six abstracts across various gastrointestinal cancers during the 2022 American Society of Clinical Oncology ...

Dec 23, 2021, 18:30 ET INVESTIGATIONAL ALZHEIMER'S DISEASE THERAPY LECANEMAB GRANTED FDA FAST TRACK DESIGNATION

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts,...

Dec 07, 2021, 11:36 ET Eisai Presents Its Largest Real-World Study Of Anti-Epileptic Drug FYCOMPA® (perampanel) Across Patient Types At The 2021 American Epilepsy Society (AES) Annual Meeting

Eisai Inc. presented data from PERMIT, a large real-world clinical study evaluating its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII,...

Dec 07, 2021, 08:35 ET #ThisIsMBC "fearLESS" Campaign Portrays Powerful Portraits of People Living fearLESSly with Metastatic Breast Cancer Through Friendship, Community and Making Each Day Count

Eisai Inc. and METAvivor today announced the launch of fearLESS, a new initiative of the #ThisIsMBC campaign. FearLESS showcases content of a diverse ...

Dec 07, 2021, 08:00 ET Eisai Presents Final Results Of Phase IV Elevate Study Of Anti-Epileptic Drug FYCOMPA® (perampanel) At The American Epilepsy Society (AES) 2021 Annual Meeting

Eisai Inc. presented analyses of the ELEVATE study of its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII at the 2021 American Epilepsy Society...

Dec 01, 2021, 15:15 ET Eisai To Present Real-World Evidence And Convulsive Seizure Freedom Data Evaluating FYCOMPA® (perampanel) Across Patient Types At 75th American Epilepsy Society (AES) Annual Meeting

Eisai Inc. announced today that new data on its antiepileptic drug FYCOMPA® (perampanel) CIII will be presented at the 75th American Epilepsy Society ...

Nov 11, 2021, 12:00 ET Introduction of First-Of-A-Kind Plasma-Based Biomarker Screening To Facilitate Identification Of Subjects For Phase 3 Ahead 3-45 Trial Presented At Clinical Trials On Alzheimer's Disease (CTAD) Conference

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts,...

Nov 11, 2021, 11:20 ET Eisai Presents New Analysis Of Lecanemab Clinical Efficacy Results From Phase 2b Study At Clinical Trials On Alzheimer's Disease (CTAD) Conference

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts,...

Nov 10, 2021, 14:57 ET Eisai Presents Late-Breaker Updates On Lecanemab Clinical, Biomarker And Safety Data From Phase 2b Study Core And Open-Label Extension Across Five Years At Clinical Trials On Alzheimer's Disease (CTAD) Conference

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts,...

Nov 08, 2021, 11:00 ET DIAN-TU Selects Lecanemab As Background Anti-Amyloid Therapy In Clinical Trial Evaluating Investigational Therapy Targeting Tau For Dominantly Inherited Alzheimer's Disease

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the Dominantly Inherited Alzheimer Network Trials Unit...

Nov 04, 2021, 08:10 ET Eisai Presents New Data on the Relationship between Clinical, Biomarker and Safety Outcomes from the Lecanemab Phase 2b Study for Early Alzheimer's disease in Late-Breakers and Pipeline Updates at the Clinical Trials on Alzheimer's Disease (CTAD) Conference

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the presentation of data from the company's extensive Alzheimer's...

Sep 27, 2021, 19:30 ET Eisai Initiates Rolling Submission To The U.S. FDA For Biologics License Application Of Lecanemab (BAN2401) For Early Alzheimer's Disease Under The Accelerated Approval Pathway

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts,...

Sep 13, 2021, 08:08 ET Data at ESMO Congress 2021 Underscore Depth of Eisai's Oncology Pipeline and Commitment to Cancer Care

Eisai Inc. announced today the presentation of 13 abstracts across multiple types of cancer from its oncology portfolio during the upcoming European...

Aug 30, 2021, 07:55 ET Eisai Announces New Executive Leadership Team at H3 Biomedicine

Eisai today announced that H3 Biomedicine (H3), its cancer genomics-based drug discovery subsidiary company located in Cambridge, Mass., has...